Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tivantinib

- PMLiVE

Medscape Oncology and American Society of Clinical Oncology Collaborate to Offer Cancer-Specific Training to Multidisciplinary Members of the Oncology Care Team

This week Medscape Oncology announced an exciting collaboration with  ASCO® which you read on the Cision PR news wire here or below:The American Society of Clinical Oncology (ASCO®), a leader at...

Medscape Education Global

- PMLiVE

Almirall survey reveals limited knowledge of most common precancerous skin condition

Up to 80% of squamous cell carcinomas develop from actinic keratosis lesions

- PMLiVE

Medscape Education is Focusing on Patient Centricity and Education Outcomes at EHA 2023

The Medscape Education team will be on site at the 2023 EHA conference in Frankfurt, Germany to share the outcomes of recent hematology education programs and to advance the discussion on...

Medscape Education Global

- PMLiVE

Amgen’s Lumakras shows promise in phase 3 lung cancer study

The company has also presented results from a study of Lumakras in colorectal cancer

- PMLiVE

AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer

An estimated 2.2 million people worldwide are diagnosed with lung cancer each year

- PMLiVE

BMS presents positive four-year results for Opdivo combination in lung cancer

NSCLC is the most common type of lung cancer, representing up to 85% of diagnoses

- PMLiVE

Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment

Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

Avalere Health

- PMLiVE

Researchers at ICR London discover new nutrient source for cancer growth

Study reveals new findings of dietary changes within pancreatic cancer cells

- PMLiVE

AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer

An estimated 2.2 million people worldwide are diagnosed with lung cancer each year

- PMLiVE

AI model shows promise in detecting lung cancer earlier

Lung cancer accounts for more than 20% of cancer deaths in the UK

- PMLiVE

Bristol Myers Squibb and Tubulis partner in deal worth over $1bn

The agreement is aimed at developing differentiated ADCs for solid tumours

- PMLiVE

ICR and NeoPhore announce immuno-oncology collaboration to develop new cancer drugs

The partners will evaluate the effect of NeoPhore’s small molecule inhibitors on tumours

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links